Intech Biopharm Total Current Liabilities

The latest total current liabilities for 6461.TWO is $230M as of June 2026. That compares with $450M in the prior-year period — down 48.6% year over year. Investors often review this figure alongside Intech Biopharm's historical trend and sector peers before judging valuation or financial health.

Over the past year, 6461.TWO's total current liabilities moved from $450M to $230M — a 48.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Intech Biopharm's operating scale or balance-sheet position.

A total current liabilities figure of $230M for 6461.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 6461.TWO's total current liabilities ($230M), review year-over-year change from $450M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Intech Biopharm's total current liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.